Bob Lutz
Chief Development Officer Synthis Therapeutics
Seminars
Thursday 19th March 2026
Investment & Partnership Panel – Accelerating Innovation in Conjugate Therapeutics
9:00 am
Hear directly from VCs and pharma BD leaders on what data packages, formats, and strategies attract investment:
- What pharma wants: therapeutic index, MoA clarity, and early efficacy signals
- Pre-IND vs. Phase I: where investors draw the line on risk
- Collaboration models and platform licensing strategies
Tuesday 17th March 2026
Designing Holistically: Aligning Targeting Scaffold & Payload Strategy in Novel Conjugates
9:00 am
This workshop explores how targeting format, payload, and linker choices interact to shape efficacy, safety, and clinical strategy, by bringing together a unique audience across the targeting format and payload landscape to understand where different modalities can complement one another for success.
- Understand how targeting format (monoclonal, bispecific, antibody fragment, peptide) influences payload selection and mechanism of action
- Evaluate whether monoclonal antibodies remain optimal for emerging payloads such as degraders and oligonucleotides
- Compare design trade-offs between bispecific targeting and payload potency, stability, and exposure
- Explore compatibility challenges and linker considerations when combining new payload types with novel scaffolds
- Develop an integrated design framework that connects discovery, chemistry, and translational perspectives
